Mergers & Acquisitions ·
Lantheus Holdings, Inc. entered into a definitive Agreement and Plan of Merger with Curium US Holdings LLC on August…
LNTHLantheus Holdings, Inc.
Lantheus Holdings, Inc. entered into a definitive Agreement and Plan of Merger with Curium US Holdings LLC on August 3, 2026, pursuant to which Lantheus will be acquired in an all-cash transaction valued at $102.50 per share. The consideration includes one contractual contingent value right (CVR) per share, entitling holders to receive up to $12.00 in cash upon the achievement of specific commercial milestones for the Global Prostate Cancer Diagnostics, Global Neurology Diagnostics, and Global DEFINITY franchises. The merger is not subject to any financing condition, with Parent having secured equity and debt commitments. Closing is conditioned on stockholder approval, regulatory clearances including Hart-Scott-Rodino expiration, and the absence of a Material Adverse Effect. If terminated under specific circumstances, Curium must pay Lantheus a $385 million termination fee or a $100 million regulatory fee. The company operates in the medical diagnostics industry, specializing in radiopharmaceuticals for oncology and neurology.